Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition

Trial Profile

Define in Preclinical Diastolic Dysfunction (PDD) With Renal Dysfunction, the Cardiorenal and Humoral Actions of Chronic Type V Phosphodiesterase (PDEV) Inhibition

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 03 Jan 2015

At a glance

  • Drugs Tadalafil (Primary)
  • Indications Kidney disorders; Left ventricular dysfunction
  • Focus Pharmacodynamics
  • Acronyms Aim3
  • Most Recent Events

    • 02 Sep 2014 Planned End Date changed from 1 Mar 2018 to 1 Jun 2018 as reported by ClinicalTrials.gov record.
    • 02 Sep 2014 Planned primary completion date changed from 1 Oct 2017 to 1 Mar 2018 as reported by ClinicalTrials.gov record.
    • 02 Sep 2014 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top